Ertapenemisanewcarbapenemdevelopedtoaddressthepharmacokineticshortcomings(shorthalf-life)ofimipenemandmeropenem.Ertapenemsharessimilarstructuralfeatureswithmeropenem,includingitsstABIlitytodehydropeptidase-1,allowingittobeadmiNISTeredwithoutadehydropeptidase-1inhibitor.Ertapenem,likeimipenemandmeropenem,demonstratesbroad-spectrumantimicrobialactivityagainstmanyGram-positiveand-negativeaerobesandanaerobesandisresistanttonearlyallβ-lactamases,includingextended-spectrumβ-lactamasesandAmpCs. Theextensiveproteinbindingofertapenemextendsthehalf-lifeandallowsforonce-dailydosing. Ertapenembindstopenicillinbindingproteins(PBPs)locatedonthebacterialcellwall,inparticularPBPs2and3,therebyinhibitingthefinaltranspeptidationstepinthesynthesisofpeptidoglycan,anessentialcomponentofthebacterialcellwall.Inhibitionofpeptidoglycansynthesisresultsinweakeningandlysisofthecellwallandcelldeath.
ErtapenemisaparenteralcarbapenemwhichiscurrentlyapprovedintheUnitedStatesforuseinthetreatmentofintraaBDominalinfections,complicatedskinandsoft-tissueinfections,community-acquiredpneumonia,andcomplicatedurinarytractinfections.Ertapenemisuniqueforitslongeliminationhalf-life,whichallowsforonce-dailydosing.Becauseofitsbroadspectrumofactivity,itisoftenusedforthetreatmentofinfectionsrequiringprolongedparenteraltherapy.
AdditionalInformation
| Product# | E-2497 |
|---|---|
| CAS# | 153773-82-1 |
| Formula | C22H24N3NaO7S |
| MW | 497.5 |
| Appearance | Whitetolightyellowpowder |
| Purity | >90% |
| Solubility | Solubleinwater |
| StorageTemp | Storeat+4°C |
| TherapeuticArea | IndicatedforthetreatmentofadultpatientsandpediatricpatientswithComplicatedIntra-AbdominalInfections,CommunityAcquiredPneumoniaandUrinaryTractInfectionsIncludingPyelonephritis. |
| Use | Abroadspectrumantibiotic. |
